Gap19 TFA

• CAT Number: I045999
• Molecular Formula: C57H97F3N14O15
• Molecular Weight: 1275.46
• Purity: ≥95%
• Synonyms: (2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]hexanoic acid;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C55H96N14O13.C2HF3O2/c1-5-33(3)45(69-51(77)40(25-27-44(71)72)65-54(80)46(34(4)6-2)68-50(76)39(24-26-43(61)70)62-47(73)36(60)20-10-14-28-56)53(79)64-38(22-12-16-30-58)48(74)63-37(21-11-15-29-57)49(75)67-42(32-35-18-8-7-9-19-35)52(78)66-41(55(81)82)23-13-17-31-59;3-2(4,5)1(6)7/h7-9,18-19,33-34,36-42,45-46H,5-6,10-17,20-32,56-60H2,1-4H3,(H2,61,70)(H,62,73)(H,63,74)(H,64,79)(H,65,80)(H,66,78)(H,67,75)(H,68,76)(H,69,77)(H,71,72)(H,81,82);(H,6,7)/t33-,34-,36-,37-,38-,39-,40-,41-,42-,45-,46-;/m0./s1
• InChIKey: UBIXVFFLYALTSN-TWIANDLUSA-N
• SMILES: CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CCCCN)C(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)N.C(=O)(C(F)(F)F)O

Gap19 TFA(CAT: I045999) is a selective connexin 43 (Cx43) hemichannel blocker derived from nine amino acids of the Cx43 cytoplasmic loop (CL). It prevents intramolecular C-terminal (CT)–CL interactions, thereby inhibiting hemichannel opening without affecting Cx43 gap junction channels, Cx40, or pannexin-1 hemichannels. Gap19 TFA suppresses unitary hemichannel currents in HeLa-Cx43 cells (400 μM) and ventricular cardiomyocytes (100 μM). At 250 μM, it decreases mitochondrial potassium uptake and protects against ischemia/reperfusion (I/R) injury in vitro. In vivo, intravenous administration (25 mg/kg) significantly reduces infarct size. With cardioprotective and hemichannel-specific actions, Gap19 TFA is a valuable tool in cardiovascular and mitochondrial research.